(888) 552-6760 SCHEDULE A CONSULTATION
Clinical-Trials

Clinical trials

Search our clinical trials

Cancer Treatment Centers of America® (CTCA) is committed to providing new and innovative treatments for our cancer patients whenever possible. This includes enrolling qualified patients in carefully selected clinical trials for cancer. Clinical trials are a key testing ground for determining the effectiveness and safety of new treatments and drugs for cancer and other diseases. Our doctors may recommend that cancer patients enroll in cancer clinical trials if they meet specific criteria. Cancer trials may offer patients access to treatment options that would otherwise be unavailable to them. Talk to your doctor about whether a cancer trial is a good option for you and ask about the risks and various requirements involved. Use the tool below to find a CTCA® clinical trial for your cancer type.

Filters

7 Clinical Trials

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is a global phase 2, multi-center, single-arm, open label study of taletrectinib in patients of NSCLC harboring with ROS1 fusion gene.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This study employs a two-stage design that aims to evaluate the efficacy and safety of ENV-101, a potent hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF) mutations in the patched-1 (PTCH1) gene.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

TAPISTRY is a Phase 2, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay. Participants with solid tumors will be treated with a drug or drug regimen tailored to their NGS assay results at screening. Participants will be assigned to the appropriate cohort based on their genetic alteration(s). Treatment will be assigned on the basis of relevant oncogenotype, will have cohort-specific inclusion/exclusion criteria, and, unless otherwise specified, will continue until disease progression, loss of clinical benefit, unacceptable toxicity, participant or physician decision to discontinue, or death, whichever occurs first.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

The primary objectives of the study are to evaluate the safety, tolerability, and recommended phase 2 dose (RP2D) of magrolimab + docetaxel combination therapy in solid tumors.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This will be a Phase 1 Open-label, dose escalation and expansion study of MT-6402 (an Engineered Toxin Body (ETB)) in subjects with advanced solid cancer that expresses PD-L1

The TAPUR study is a clinical trial that aims to improve our understanding of how commercially available anti-cancer drugs perform on a broader range of cancers, by matching the drugs to tumors with specific genomic mutations that the drugs are designed to target.